Andrew Pellegrin, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W Bldg 1040, Jbsa Randolph, TX 78150 Phone: 210-652-8544 |
Mary Temitope Ileso, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W Bldg 1040, Jbsa Randolph, TX 78150 Phone: 210-652-4127 |
Dr. Christopher Mclaughlin, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 63 Main Cir Ste 3, Jbsa Randolph, TX 78150 Phone: 210-652-6403 |
Dr. William I Lin, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W Bldg 1040, Jbsa Randolph, TX 78150 Phone: 830-298-6538 |
Alexander Sparkman-royo, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W Bldg 1040, Jbsa Randolph, TX 78150 Phone: 575-784-1104 |
Dr. Kasey Carl Welch, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 221 3rd St W Bldg 1040, Jbsa Randolph, TX 78150 Phone: 210-652-4264 |
Dr. Cecelia Mariko Luda, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W, Jbsa Randolph, TX 78150 Phone: 210-565-0685 |
Dr. Karla Renise Ivy, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 221 3rd St W Bldg 1040, Jbsa Randolph, TX 78150 Phone: 210-652-5363 |
Dr. Ian David Gregory, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W, Jbsa Randolph, TX 78150 Phone: 201-652-8500 |
News Archive
Preventing lung infections in childhood could stop later life-threatening infections for people with cystic fibrosis (CF), according to the latest research carried out at Aston University.
IFR microbiologists are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals.
Building on their earlier work, Johns Hopkins researchers have discovered that an apparently nontoxic cellular "energy blocker" can eradicate large liver tumors grown in rats. Six months to more than a year after treatment was stopped, the rats are still cancer free.
Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.
› Verified 3 days ago